Página 71 - v24n1

bado lo que se ha publicado actualmente, se debería reconsi-
derar el uso de la terapéutica biológica en la alopecia areata21.
REFERENCIAS
1. García Hernández MJ. Alopecia areata: Un síndrome heterogé-
neo. Tesis Doctoral. Sevilla, 1997.
2. Nickoloff BJ, Stevens SR. What have we learned in dermatology
from the biologic therapies? J Am Acad Dermatol 2006; 54
(S2): 143-51.
3. Jacobi A, Mahles V, Schuler G, Hertl M. Treatment of inflamma-
tory dermatoses by tumour necrosis factor antagonist. J Eur Acad
Dermatol Venereol 2006; 20: 1171-87.
4. López Estebarán JL. Tratamiento con infliximab de la psoriasis en
placas. En Fonseca Capdevila E. (ed). Terapias biológicas para
los psoriasis. Madrid: Artes Graficas Grupo SA. 2006; 7-20.
5. Moreno Giménez JC. Etanercept en el tratamiento de la psoriasis
en placas. En Fonseca Capdevila E. (ed). Terapias biológicas para
los psoriasis. Madrid: Artes Gráficas Grupo SA. 2006; 42-51.
6. Ferrándiz C. Efalizumab en el tratamiento de la psoriasis en pla-
cas. En Fonseca Capdevila E. (ed). Terapias biológicas para los
psoriasis. Madrid: Artes Gráficas Grupo SA. 2006; 42-51.
7. Daudén Tello E. Adalimumab en el tratamiento de la psoriasis en
placas. En Fonseca Capdevila E. (ed). Terapias biológicas para
los psoriasis. Madrid: Artes Gráficas Grupo SA. 2006; 52-62.
8. Heffernan MP, Hurley MY, Martin KS, Smith DI, Anadkat MJ. Ale-
facept for alopecia areata. Arch Dermatol 2005; 141: 1513-6.
9. Reddy M, Torres G, McCornick T, Marano C, Cooper K, Yeilding N,
Wang Y, Pendley C et al. Positive treatment effects of ustek-
inumab in psoriasis: analysis of lesional and systemic parame-
ters. J Dermatol 2010; 37: 413-25.
10. Macdonald-Hull S, Nutbrown M, Pepall L et al. Immunohistologic
and ultrastructural comparison of the dermal papilla and hair fol-
licle bulb from “active” and “normal” areas of alopecia areata.
J Invest Dermatol 1991; 96: 673-81.
11. Philpott MP, Sanders DA, Boween J, Kealey T. Effects of inter-
leukins, colony stimulating factor and tumour necrosis factor on
hair follicle growth in vitro: a possible role for interleukin-1 and
tumour necrosis factor- in alopecia areata. Br J Dermatol 1996;
135: 942-8.
12. Gilhar A, Landau M, Assy B, Ullmann Y, Shlaginov R, Serafimovich
S, Kalish RS. Transfer of alopecia areata in the human scalp
graft/Prkdc(SCID) mouse system is characterized by a TH1
response. Clin Inmunol 2003; 106: 181-7.
13. Kaelin U, Hassan AS, Braathen LR, Yawalkar N. Treatment of
alopecia areata partim universalis with eflizumab. J Am Acad
Dermatol 2006; 55: 529-32.
14. Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient
using infliximab: new insights into the role of tumor necrosis fac-
tor on human follicles. Arch Dermatol 2004; 140: 1012.
15. Bui K, Polisetty S, Gilchrist H, Jackson SM, Frederic J. Successful
treatment of alopecia universalis with alefacept: a case report
and review of the literature. Cutis 2008; 81: 431-4.
16. Strober BE, Siu K, Alexis AF, Kim G, Washenik K, Sinha A et al.
Etanercept does not effectively treat moderate to severe alope-
cia areata: an open-label study. J Am Acad Dermatol 2005; 52:
159-63.
17. Posten W, Swan J. Recurrence of alopecia areata in a patient receiv-
ing etanercept injections. Arch Dermatol 2005; 141: 759-60.
18. Pan Y, Rao NA. Alopecia areata during etanercept therapy. Ocul
Immunol Inflamm 2009; 13: 48-50.
19. Ferran M, Calvet J, Almirall M et al. Alopecia areata as another
immune-mediated disease developed in patients treated with
tumour necrosis factor- blocker agents. JEADV 2010 (articles
online in advance of print).
20. Price VH, Hordinsky MK, Olsen EA et al. Subcutaneuos efal-
izumab is not effective in the treatment of alopecia areata. J Am
Acad Dermatol 2008; 58: 395-402.
21. Tosti A, Pazzaglia M, Strace M, Bellavista S, Vicenzi C, Tonelli G.
Alopecia areata during treatment with biologic agents. Arch Der-
matol 2006; 142: 1653-4.
22. Fabre C, Dereure O. Worsening alopecia areata and de novo
occurrence of multiple halo nevi in a patient receiving infliximab.
Dermatology 2008; 216: 185-6.
23. Nakagomi D, Harada K, Yagasaki A, Kawamura T, Shibagaki N, Shi-
mada S. Psoriasiform eruption associated with alopecia areata dur-
ing infliximab therapy. Clin Exp Dermatol 2009; 34: 923-4.
24. García-Bartels N, Lee HH, Worm M, Burmester GR, Sterry W,
Blume-Peytavi U. Development of alopecia areata universalis in
a patient receiving adalimumab. Arch Dermatol 2006; 142:
1654-5.
25. Pelivani N, Hassan AS, Braathen LR, Hunger RE, Yawalkar N.
Alopecia Areata Universalis Elicited during Treatment with Adali-
mumab. Dermatology 2008; 216: 320-3.
26. Chaves Y, Duarte G, Ben-Said B, Tebib J, Berard F, Nicolas JF.
Alopecia areata universales during treatment of rheumatoid artri-
tis with TNF-α antibody (adalimumab). Dermatology 2008;
217: 380.
27. Kirshen C, Kanigsberg N. Alopecia areata following adalimumab.
J Cutan Med Surg 2009; 13: 48-50.
28. Katoulis AC, Alevizou A, Bozo E et al. Biologic agents and alope-
cia areata. Dermatology 2009; 218: 184-5.
29. Neila J, Carrizosa A, Ceballos C, Camacho F. Alopecia areata y
terapias biológicas. Presentación de un caso asociado a adalimu-
mab. Actas Dermosifiliogr 2011 (En prensa).
30. Slowinska M, Kardynal A, Warszawik O, Czuwara J, Rudnicka L.
Development of alopecia areata parallel to psoriasis improve-
ment in a patient treated with ustekinumab. Poster 377. 19 Con-
greso de la Academia Europea de Dermatología y Venereología.
Goteborg, 6-10 Octubre 2010.
31. Alkhalifah A, Alsantalia A, Wang E et al. Alopecia areata update.
Part II. Treatment. J Am Acad Dermatol 2010; 62: 191-202.
Monografías de Dermatología 68